Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy , Safety, and Predictors of Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer in a Real-world Setting

NCT06011330 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT06011330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06011330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy , Safety, and Predictors of Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer in a Real-world Setting
Lead sponsor
Hunan Cancer Hospital
Phase
Observational
Overall status
Completed
Start date
January 1, 2019
Completion date
February 10, 2023
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer